MX2018015759A - Regimenes de dosificacion de vortioxetina para el rapido inicio del efecto antidepresivo. - Google Patents
Regimenes de dosificacion de vortioxetina para el rapido inicio del efecto antidepresivo.Info
- Publication number
- MX2018015759A MX2018015759A MX2018015759A MX2018015759A MX2018015759A MX 2018015759 A MX2018015759 A MX 2018015759A MX 2018015759 A MX2018015759 A MX 2018015759A MX 2018015759 A MX2018015759 A MX 2018015759A MX 2018015759 A MX2018015759 A MX 2018015759A
- Authority
- MX
- Mexico
- Prior art keywords
- vortioxetine
- composition
- steady
- antidepressant effect
- fast onset
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Inorganic Chemistry (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Psychiatry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Un régimen de dosificación que comprende la administración simultánea de dos composiciones farmacéuticas, en donde la primera composición farmacéutica es una composición que comprende vortioxetina o una sal farmacéuticamente aceptable de la misma para una administración oral una vez al día, y la segunda composición farmacéutica es una composición que comprende vortioxetina o una sal farmacéuticamenteaceptable de la misma que, junto con la primera composición, logra rápidamente un nivel en plasma de estado estacionario de vortioxetina en el paciente, nivel en plasma de estado estacionario que es esencialmente elmismo que el nivel en plasma de estado estacionario de vortioxetina logrado por la administración al paciente de la primera composición sola.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662357722P | 2016-07-01 | 2016-07-01 | |
| PCT/EP2017/065958 WO2018002115A1 (en) | 2016-07-01 | 2017-06-28 | Vortioxetine dosing regimes for fast onset of antidepressant effect |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2018015759A true MX2018015759A (es) | 2019-03-21 |
Family
ID=59239917
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018015759A MX2018015759A (es) | 2016-07-01 | 2017-06-28 | Regimenes de dosificacion de vortioxetina para el rapido inicio del efecto antidepresivo. |
Country Status (17)
| Country | Link |
|---|---|
| US (4) | US9820984B1 (es) |
| EP (1) | EP3478289A1 (es) |
| JP (1) | JP2019524682A (es) |
| KR (1) | KR20190025556A (es) |
| CN (1) | CN109310691A (es) |
| AU (1) | AU2017288456A1 (es) |
| BR (1) | BR112018003930A2 (es) |
| CA (1) | CA3026728A1 (es) |
| CL (1) | CL2018003707A1 (es) |
| CO (1) | CO2018013792A2 (es) |
| IL (1) | IL263584A (es) |
| MA (1) | MA45532A (es) |
| MX (1) | MX2018015759A (es) |
| RU (1) | RU2018144248A (es) |
| SG (1) | SG11201810644TA (es) |
| TW (1) | TW201806599A (es) |
| WO (1) | WO2018002115A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112018003930A2 (pt) * | 2016-07-01 | 2018-09-25 | H Lundbeck As | regimes de dosagem de vortioxetina para início rápido de efeito antidepressivo |
| US20210393621A1 (en) | 2018-10-26 | 2021-12-23 | The Research Foundation For The State University Of New York | Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA81749C2 (uk) | 2001-10-04 | 2008-02-11 | Х. Луннбек А/С | Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну |
| EP2439201B1 (en) | 2006-06-16 | 2013-08-07 | H. Lundbeck A/S | Compounds with combined sert, 5-ht3 and 5-ht1a activity |
| HRP20110412T1 (hr) | 2006-06-16 | 2011-06-30 | H. Lundbeck A/S | Kristalni oblici 4-[2-4-(4-metilfenilsulfanil)fenil]piperidina sa kombiniranom inhibicijom reapsorpcije serotonina i norepinefrina za liječenje neuropatskih bolova |
| TW200848411A (en) * | 2007-03-20 | 2008-12-16 | Lundbeck & Co As H | Novel therapeutic uses of 1-[2-(2, 4-dimethylphenylsulfanyl)phenyl]-piperazine |
| TWI432194B (zh) | 2007-03-20 | 2014-04-01 | Lundbeck & Co As H | ４-〔２-（４-甲基苯硫基）苯基〕哌啶之新穎治療用途 |
| TW200932233A (en) | 2007-11-13 | 2009-08-01 | Lundbeck & Co As H | Therapeutic uses of compounds having combined SERT, 5-HT3 and 5-HT1a activity |
| TW201033181A (en) | 2009-02-17 | 2010-09-16 | Lundbeck & Co As H | Purification of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine |
| HRP20140880T1 (hr) | 2009-04-24 | 2014-11-07 | H. Lundbeck A/S | Tekuä†a formulacija soli 1-/2-(2,4 dimetilfenilsulfanil)fenil/piperazina |
| ME01602B (me) | 2009-08-24 | 2014-09-20 | H Lundbeck As | Nove kompozicije 1-[2 -(2,4-dimetil-fenilsulfanil)-fenil]piperazina |
| TW201212918A (en) | 2010-08-23 | 2012-04-01 | Lundbeck & Co As H | Therapeutic uses of 1-[2-(2,4-dimethyl-phenylsulfanyl)phenyl]piperazine |
| SG11201403835UA (en) | 2012-01-03 | 2014-10-30 | Lundbeck & Co As H | Process for the manufacture of 1-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]-piperazine |
| KR102171152B1 (ko) | 2012-12-13 | 2020-10-29 | 하. 룬드벡 아크티에셀스카브 | 보르티옥세틴 및 도네페질을 포함하는 조성물 |
| RS55932B1 (sr) | 2013-02-22 | 2017-09-29 | H Lundbeck As | Postupak za proizvodnju vortioksetina |
| AU2014368548B2 (en) | 2013-12-20 | 2019-09-19 | H. Lundbeck A/S | Use of an opioid receptor antagonist with kappa-activity and vortioxetine for treatment of depressive disorder with melancholic features |
| JO3456B1 (ar) | 2015-05-13 | 2020-07-05 | H Lundbeck As | فيروتيوكسيتين بيروجلوتامات |
| BR112018003930A2 (pt) * | 2016-07-01 | 2018-09-25 | H Lundbeck As | regimes de dosagem de vortioxetina para início rápido de efeito antidepressivo |
-
2017
- 2017-06-28 BR BR112018003930A patent/BR112018003930A2/pt not_active Application Discontinuation
- 2017-06-28 US US15/636,238 patent/US9820984B1/en not_active Expired - Fee Related
- 2017-06-28 SG SG11201810644TA patent/SG11201810644TA/en unknown
- 2017-06-28 MA MA045532A patent/MA45532A/fr unknown
- 2017-06-28 JP JP2018568721A patent/JP2019524682A/ja active Pending
- 2017-06-28 CN CN201780033672.4A patent/CN109310691A/zh active Pending
- 2017-06-28 EP EP17733829.0A patent/EP3478289A1/en not_active Withdrawn
- 2017-06-28 WO PCT/EP2017/065958 patent/WO2018002115A1/en not_active Ceased
- 2017-06-28 TW TW106121573A patent/TW201806599A/zh unknown
- 2017-06-28 AU AU2017288456A patent/AU2017288456A1/en not_active Abandoned
- 2017-06-28 RU RU2018144248A patent/RU2018144248A/ru not_active Application Discontinuation
- 2017-06-28 CA CA3026728A patent/CA3026728A1/en not_active Abandoned
- 2017-06-28 KR KR1020187036532A patent/KR20190025556A/ko not_active Withdrawn
- 2017-06-28 MX MX2018015759A patent/MX2018015759A/es unknown
- 2017-09-13 US US15/703,572 patent/US9913839B2/en not_active Expired - Fee Related
-
2018
- 2018-02-06 US US15/890,006 patent/US10258617B2/en not_active Expired - Fee Related
- 2018-12-09 IL IL263584A patent/IL263584A/en unknown
- 2018-12-19 CO CONC2018/0013792A patent/CO2018013792A2/es unknown
- 2018-12-20 CL CL2018003707A patent/CL2018003707A1/es unknown
-
2019
- 2019-03-04 US US16/291,865 patent/US20200030319A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2017288456A1 (en) | 2018-12-13 |
| SG11201810644TA (en) | 2018-12-28 |
| MA45532A (fr) | 2019-05-08 |
| JP2019524682A (ja) | 2019-09-05 |
| US20180000815A1 (en) | 2018-01-04 |
| US10258617B2 (en) | 2019-04-16 |
| US20180153881A1 (en) | 2018-06-07 |
| EP3478289A1 (en) | 2019-05-08 |
| TW201806599A (zh) | 2018-03-01 |
| CL2018003707A1 (es) | 2019-02-15 |
| US20200030319A1 (en) | 2020-01-30 |
| US9820984B1 (en) | 2017-11-21 |
| CN109310691A (zh) | 2019-02-05 |
| CO2018013792A2 (es) | 2019-01-18 |
| BR112018003930A2 (pt) | 2018-09-25 |
| RU2018144248A (ru) | 2020-08-03 |
| IL263584A (en) | 2019-01-31 |
| WO2018002115A1 (en) | 2018-01-04 |
| CA3026728A1 (en) | 2018-01-04 |
| KR20190025556A (ko) | 2019-03-11 |
| US9913839B2 (en) | 2018-03-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201690102A1 (ru) | Фармацевтическая композиция, содержащая диметилфумарат, для введения в низкой суточной дозе | |
| MX351584B (es) | Formulacion farmaceutica acuosa de tapentadol para administracion oral. | |
| UA106636C2 (uk) | Морфолінотіазоли як позитивні алостеричні модулятори альфа 7 | |
| BR112017001968A2 (pt) | embalagem de duas câmaras para uma composição farmacêutica líquida oral de múltiplas doses | |
| EA201491479A1 (ru) | Производные лупановых тритерпеноидов и их фармацевтическое применение | |
| AR101674A1 (es) | Uso de un compuesto tricíclico que contiene nitrógeno | |
| AR096892A1 (es) | Una combinación farmacéutica para el tratamiento del melanoma | |
| CO2017002682A2 (es) | Composiciones y métodos para recubrimientos cannabinoides para uso en la entrega de fármacos | |
| MX2018000546A (es) | Composiciones farmaceuticas que contienen celecoxib y tramadol. | |
| MY165888A (en) | Dry powder formulation comprising a corticosteroid and a beta-adrenergic for administration by inhalation | |
| EA201691918A1 (ru) | Фармацевтические составы ингибитора киназ семейства raf, способы их получения и способы их применения | |
| MX380070B (es) | Una composición farmacéutica que comprende amlodipino, valsartán y rosuvastatina. | |
| WO2012145575A3 (en) | Therapy for leukemia | |
| EA201501164A1 (ru) | Твердая фармацевтическая лекарственная форма | |
| UA118474C2 (uk) | (s)-пірліндол та його фармацевтично прийнятні солі для застосування в медицині | |
| MX2016008027A (es) | Uso de laquinimod para retrasar la evolucion de la enfermedad de huntington. | |
| MX2018015759A (es) | Regimenes de dosificacion de vortioxetina para el rapido inicio del efecto antidepresivo. | |
| PH12018500817A1 (en) | Pharmaceutical composition comprising metformin and lobeglitazone | |
| PH12016500120A1 (en) | Anti-tuberculosis stable pharmaceutical composition in a form of a coated tablet comprising granules of isoniazid and granules of rifapentine and its process of preparation | |
| EA201890929A1 (ru) | Низкие дозировки композиций дипиридамола для перорального приема и их использование | |
| UA116499C2 (uk) | (r)-пірліндол та його фармацевтично прийнятні солі для застосування в медицині | |
| EA201500446A1 (ru) | Фармацевтическая композиция для снижения уровня n-оксида триметиламина | |
| MX358211B (es) | Una composición farmacéutica de liberación comprendiendo hidroclorotiazida, losartán y basilato de amlodipino. | |
| EA201991359A1 (ru) | Фармацевтические лекарственные формы | |
| PH12015501313B1 (en) | Chloroprocaine-based pharmaceutical composition for repeated intrathecal administration |